• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novaccess Global Inc (OP: XSNX )

    0.0083 UNCHANGED
    Streaming Delayed Price Updated: 3:16 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.0083
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0083
    Today's Range 0.0083 - 0.0083
    52wk Range 0.0037 - 0.0540
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
    Via ACCESSWIRE
    NovAccess Global Advisory on Annual Meeting of Shareholders
    Via ACCESSWIRE

    Performance

    YTD
    -70.36%
    -70.36%
    1 Month
    +9.21%
    +9.21%
    3 Month
    -17.00%
    -17.00%
    6 Month
    +31.75%
    +31.75%
    1 Year
    -79.25%
    -79.25%

    More News

    Read More
    NovAccess Global Announces New License to Advance its Immunotherapy Platform
    Via ACCESSWIRE
    NovAccess Global Announces $10.7 Million Financing
    Via ACCESSWIRE
    NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
    Via ACCESSWIRE
    NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
    Via ACCESSWIRE
    NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
    Via ACCESSWIRE
    Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
    Via ACCESSWIRE
    NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
    Via ACCESSWIRE
    NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
    Via ACCESSWIRE
    NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
    Via ACCESSWIRE
    NovAccess Global to Present at World Orphan Drug Congress
    Via ACCESSWIRE
    NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
    Via ACCESSWIRE
    NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
    Via ACCESSWIRE
    NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
    Via ACCESSWIRE
    NovAccess Global Announces Virtual Annual Shareholders' Meeting
    Via ACCESSWIRE
    NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
    Via ACCESSWIRE
    NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
    Via ACCESSWIRE
    NovAccess Global Announces Fireside Chat with Board Member Perspectives
    Via ACCESSWIRE
    NovAccess Global Announces Fireside Chat Series for the Investment Community
    Via ACCESSWIRE
    NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
    Via ACCESSWIRE
    NovAccess Global Announces Uplisting to OTCQB
    Via ACCESSWIRE
    CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
    Via ACCESSWIRE
    NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
    Via ACCESSWIRE
    CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
    From NovAccess Global Inc.
    Via AccessWire
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.